PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL + human leukemia

Drug combination studies and their synergy quantification using the Chou-Talalay method

Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739 · see citing works

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

Druker, B. J., Tamura, S., Buchdunger, E., Ohno-Jones, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 3,618 · see citing works

Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

Druker, B. J., Guilhot, F., O’Brien, S. G., Gathmann, I., Kantarjian, H. M., Gattermann, N., Deininger, M. W., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,474 · see citing works

Sequence and structure-based prediction of eukaryotic protein phosphorylation sites

Blom, N., Gammeltoft, S., & Brunak, S. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3310 · Cited by 3,197 · see citing works

Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor

Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D. J., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,785 · see citing works

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., PAQUETTE, R. L., Kuriyan, J., & Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00096-x · Cited by 1,608 · see citing works

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

Mahon, F., Réa, D., Guilhot, J., Guilhot, F., Huguet, F., Nicolini, F. E., Legros, L., Charbonnier, A., Guerci‐Bresler, A., Varet, B. R., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70233-3 · Cited by 1,541 · see citing works

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl

Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan‐Jacob, S. W., Ray, A., Huntly, B. J. P., Fabbro, D., Fendrich, G., Hall–Meyers, E., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.007 · Cited by 1,494 · see citing works

Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML

Jamieson, C. H. M., Ailles, L. E., Dylla, S. J., Muijtjens, M., Jones, C., Zehnder, J. L., Gotlib, J., Li, K., Manz, M. G., Keating, A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040258 · Cited by 1,485 · see citing works

Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

Baccarani, M., Cortes, J. E., Pane, F., Niederwieser, D. W., Saglio, G. N., Apperley, J. F., Cervantes, F., Deininger, M. W., Gratwohl, A. A., Guilhot, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0779 · Cited by 1,276 · see citing works

The -Catenin Destruction Complex

Stamos, J. L., & Weis, W. I. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a007898 · Cited by 1,062 · see citing works

Regulation of protein kinase cascades by protein phosphatase 2A

Millward, T. A., Zołnierowicz, S., & Hemmings, B. A. (1999) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(99)01375-4 · Cited by 793 · see citing works

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

Corbin, A. S., Agarwal, A., Loriaux, M., Cortes, J., Deininger, M. W., & Druker, B. J. (2011) · Journal of Clinical Investigation · doi:10.1172/jci35721 · Cited by 765 · see citing works

Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia

Apperley, J. F. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70342-x · Cited by 641 · see citing works

Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABL

Azam, M., Latek, R. R., & Daley, G. Q. (2003) · Cell · doi:10.1016/s0092-8674(03)00190-9 · Cited by 617 · see citing works

Loss of β-Catenin Impairs the Renewal of Normal and CML Stem Cells In Vivo

Zhao, C., Blum, J. M., Chen, A., Kwon, H. Y., Jung, S., Cook, J. M., Lagoo, A. S., & Reya, T. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.11.003 · Cited by 592 · see citing works

Protein phosphatase 2A regulatory subunits and cancer

Eichhorn, P. J. A., Creyghton, M. P., & Bernards, R. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.05.005 · Cited by 513 · see citing works

The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein

Neviani, P., Santhanam, R., Trotta, R., Notari, M., Blaser, B. W., Liu, S., Mao, H. C., Chang, J. S., Galietta, A., Uttam, A., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.015 · Cited by 477 · see citing works

PP2A holoenzyme assembly: In cauda venenum (the sting is in the tail)

Janssens, V., Longin, S., & Goris, J. (2008) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2007.12.004 · Cited by 390 · see citing works

Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies

Jiang, X., Zhao, Y. S., Smith, C. A., Gasparetto, M., Turhan, A. G., Eaves, A., & Eaves, C. J. (2007) · Leukemia · doi:10.1038/sj.leu.2404609 · Cited by 359 · see citing works

Altered Microenvironmental Regulation of Leukemic and Normal Stem Cells in Chronic Myelogenous Leukemia

Zhang, B., Ho, Y., Huang, Q., Maeda, T., Lin, A., Lee, S.-U., Hair, A., Holyoake, T. L., Huettner, C. S., & Bhatia, R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.018 · Cited by 347 · see citing works

IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development

Reynaud, D., Pietras, E., Barry-Holson, K., Mir, A., Binnewies, M., Jeanne, M., Sala-Torra, O., Radich, J. P., & Passegué, E. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.10.012 · Cited by 335 · see citing works

Live-cell imaging RNAi screen identifies PP2A–B55α and importin-β1 as key mitotic exit regulators in human cells

Schmitz, M. H. A., Held, M., Janssens, V., Hutchins, J. R. A., Hudecz, O., Ivanova, E., Goris, J., Trinkle‐Mulcahy, L., Lamond, A. I., Poser, I., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2092 · Cited by 316 · see citing works

The chronic myeloid leukemia stem cell: stemming the tide of persistence

Holyoake, T. L., & Vetrie, D. L. P. (2017) · Blood · doi:10.1182/blood-2016-09-696013 · Cited by 312 · see citing works

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR

Ross, D. M., Branford, S., Seymour, J. F., Schwarer, A. P., Arthur, C. K., Bartley, P. A., Slader, C., Field, C., Dang, P. G., Filshie, R., et al. (2010) · Leukemia · doi:10.1038/leu.2010.185 · Cited by 267 · see citing works

Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate

Zhang, B., Strauss, A. C., Chu, S., Li, M., Ho, Y., Shiang, K.-D., Snyder, D., Huettner, C. S., Shultz, L. D., Holyoake, T. L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.011 · Cited by 256 · see citing works

Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment

Chu, S., McDonald, T., Lin, A., Chakraborty, S., Huang, Q., Snyder, D. S., & Bhatia, R. (2011) · Blood · doi:10.1182/blood-2010-12-327437 · Cited by 245 · see citing works

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells

Neviani, P., Harb, J. G., Oaks, J. J., Santhanam, R., Walker, C. J., Ellis, J. J., Ferenchak, G. J., Dorrance, A. M., Paisie, C. A., Eiring, A. M., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68951 · Cited by 221 · see citing works

Bcr‐Abl stabilizes β‐catenin in chronic myeloid leukemia through its tyrosine phosphorylation

Coluccia, A. M. L., Vacca, A., Duñach, M., Mologni, L., Redaelli, S., Bustos, V., Benati, D., Pinna, L. A., & Gambacorti-Passerini, C. B. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601485 · Cited by 217 · see citing works

Identification of PP2A Complexes and Pathways Involved in Cell Transformation

Sablina, A. A., Hector, M., Colpaert, N., & Hahn, W. C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2855 · Cited by 193 · see citing works

A PP1-PP2A phosphatase relay controls mitotic progression

Grallert, A., Boke, E., Hagting, A., Hodgson, B., Connolly, Y., Griffiths, J. R., Smith, D. L., Pines, J., & Hagan, I. M. (2015) · Nature · doi:10.1038/nature14019 · Cited by 188 · see citing works

AHI1 is required for photoreceptor outer segment development and is a modifier for retinal degeneration in nephronophthisis

Louie, C. M., Caridi, G., Lopes, V. S., Brancati, F., Kispert, A., Lancaster, M. A., Schlossman, A. M., Otto, E. A., Leitges, M., Gröne, H., et al. (2010) · Nature Genetics · doi:10.1038/ng.519 · Cited by 186 · see citing works

β-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia

Hu, Y., Chen, Y., Douglas, L., & Li, S. (2008) · Leukemia · doi:10.1038/leu.2008.262 · Cited by 177 · see citing works

Impaired Wnt–β-catenin signaling disrupts adult renal homeostasis and leads to cystic kidney ciliopathy

Lancaster, M. A., Louie, C. M., Silhavy, J. L., Sintasath, L., DeCambre, M., Nigam, S. K., Willert, K., & Gleeson, J. G. (2009) · Nature Medicine · doi:10.1038/nm.2010 · Cited by 175 · see citing works

Separation of PP2A core enzyme and holoenzyme with monoclonal antibodies against the regulatory A subunit: abundant expression of both forms in cells

Kremmer, E., Ohst, K., Kiefer, J., Brewis, N., & Walter, G. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.3.1692 · Cited by 175 · see citing works

APC Is Essential for Targeting Phosphorylated β-Catenin to the SCFβ-TrCP Ubiquitin Ligase

Su, Y., Fu, C., Ishikawa, S., Stella, A., Kojima, M., Shitoh, K., Schreiber, E. M., Day, B. W., & Liu, B. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.10.023 · Cited by 174 · see citing works

Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells

Carter, B. Z., Mak, P. Y., Mu, H. H., Zhou, H., Mak, D. H. F., Schober, W. D., Leverson, J. D., Zhang, B., Bhatia, R., Huang, X., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aag1180 · Cited by 170 · see citing works

Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms

Lu, J., Kovach, J. S., Johnson, F., Chiang, J. Y., Hodes, R. J., Lonser, R. R., & Zhuang, Z. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905930106 · Cited by 162 · see citing works

Targeting the β-catenin nuclear transport pathway in cancer

Jamieson, C., Sharma, M., & Henderson, B. R. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.04.012 · Cited by 147 · see citing works

Instability of BCR-ABL Gene in Primary and Cultured Chronic Myeloid Leukemia Stem Cells

Jiang, X., Saw, K. M., Eaves, A. C., & Eaves, C. J. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk150 · Cited by 136 · see citing works

Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial

Chung, V. M., Mansfield, A. S., Braiteh, F., Richards, D., Durivage, H. J., Ungerleider, R. S., Johnson, F., & Kovach, J. S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2299 · Cited by 129 · see citing works

A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia

Zhang, Q., Mao, J.-H., Liu, P., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813142106 · Cited by 123 · see citing works

LB100, a small molecule inhibitor of PP2A with potent chemo- and radio-sensitizing potential

Hong, C. S., Ho, W. S., Zhang, C., Yang, C., Elder, J. B., & Zhengping, Z. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1040961 · Cited by 119 · see citing works

Philadelphia chromosome‐positive acute lymphoblastic leukemia

Lee, H. J., Thompson, J. E., Wang, E. S., & Wetzler, M. (2010) · Cancer · doi:10.1002/cncr.25690 · Cited by 113 · see citing works

PR55α, a Regulatory Subunit of PP2A, Specifically Regulates PP2A-mediated β-Catenin Dephosphorylation

Zhang, W., Yang, J., Liu, Y., Chen, X., Yu, T., Jia, J., & Liu, C. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.013698 · Cited by 110 · see citing works

BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells

Schemionek, M., Elling, C., Steidl, U. G., Bäumer, N., Hamilton, A., Spieker, T., Göthert, J. R., Stehling, M., Wagers, A. J., Huettner, C. S., et al. (2010) · Blood · doi:10.1182/blood-2009-04-215376 · Cited by 94 · see citing works

Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome‐positive acute lymphoblastic leukemia

Jeha, S., Coustan‐Smith, E., Pei, D., et al. (2014) · Cancer · doi:10.1002/cncr.28598 · Cited by 79 · see citing works

AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells

Zhou, L. L., Zhao, Y. S., Ringrose, A., DeGeer, D., Kennah, E., Lin, A. E.-J., Sheng, G., Li, X., Turhan, A. G., & Jiang, X. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20072316 · Cited by 75 · see citing works

Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1–BCR-ABL–JAK2 Complex

Chen, M., Gallipoli, P., DeGeer, D., Sloma, I., Forrest, D. L., Chan, M. M. K., Lai, D., Jørgensen, H. G., Ringrose, A., Wang, H. M., et al. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt006 · Cited by 75 · see citing works

Ahi-1 , a Novel Gene Encoding a Modular Protein with WD40-Repeat and SH3 Domains, Is Targeted by the Ahi-1 and Mis-2 Provirus Integrations

Jiang, X., Hanna, Z., Kaouass, M., Girard, L., & Jolicoeur, P. (2002) · Journal of Virology · doi:10.1128/jvi.76.18.9046-9059.2002 · Cited by 72 · see citing works

Enhanced targeting of CML stem and progenitor cells by inhibition of porcupine acyltransferase in combination with TKI

Agarwal, P., Zhang, B., Ho, Y., Cook, A., Li, L., Mikhail, F. M., Wang, Y., McLaughlin, M. E., & Bhatia, R. (2016) · Blood · doi:10.1182/blood-2016-05-714089 · Cited by 70 · see citing works

BCR-Tyrosine 177 Plays an Essential Role in Ras and Akt Activation and in Human Hematopoietic Progenitor Transformation in Chronic Myelogenous Leukemia

Chu, S., Li, L., Singh, H., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4312 · Cited by 68 · see citing works

Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate

Jiang, X., Forrest, D. L., Nicolini, F. E., Turhan, A. G., Guilhot, J., Yip, C. K., Holyoake, T. L., Jørgensen, H. G., Lambie, K., Saw, K. M., et al. (2010) · Blood · doi:10.1182/blood-2009-05-222471 · Cited by 63 · see citing works

Sudden onset of the blastic phase of chronic myelogenous leukemia

Kantarjian, H. M., O'Brien, S. M., Cortes, J. E., et al. (2003) · Cancer · doi:10.1002/cncr.11477 · Cited by 57 · see citing works

Factors Affecting the Nuclear Localization of β‐Catenin in Normal and Malignant Tissue

Morgan, R. G., Ridsdale, J., Tonks, A., & Darley, R. L. (2014) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24803 · Cited by 56 · see citing works

Deregulated expression in Ph+ human leukemias of AHI-1, a gene activated by insertional mutagenesis in mouse models of leukemia

Jiang, X., Zhao, Y. S., Chan, W. Y., Vercauteren, S., Pang, E., Kennedy, S., Nicolini, F., Eaves, A. C., & Eaves, C. J. (2004) · Blood · doi:10.1182/blood-2003-11-4026 · Cited by 49 · see citing works

Deregulation of the protein phosphatase 2A, PP2A in cancer: complexity and therapeutic options

Grech, G., Baldacchino, S., Saliba, C., Grixti, M. P., Gauci, R., Magri, V. P., Fenech, A. G., & Scerri, C. A. (2016) · Tumor Biology · doi:10.1007/s13277-016-5145-4 · Cited by 48 · see citing works

Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells

Lin, H., Chen, M., Rothe, K., Lorenzi, M. V., Woolfson, A., & Jiang, X. (2014) · Oncotarget · doi:10.18632/oncotarget.2353 · Cited by 39 · see citing works

4D-networking by mitotic phosphatases

Qian, J., Winkler, C., & Bollen, M. (2013) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2013.06.005 · Cited by 33 · see citing works

Evidence for an oncogenic role of AHI-1 in Sezary syndrome, a leukemic variant of human cutaneous T-cell lymphomas

Ringrose, A., Zhou, Y., Pang, E., Zhou, L. L., Lin, A. E.-J., Sheng, G.-N., Li, X.-J., Weng, A. P., Su, M., Pittelkow, M. R., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404321 · Cited by 32 · see citing works

Enhancement of cancer chemotherapy by simultaneously altering cell cycle progression and DNA-damage defenses through global modification of the serine/threonine phospho-proteome

Zhuang, Z., Lu, J., Lonser, R. R., et al. (2009) · Cell Cycle · doi:10.4161/cc.8.20.9689 · Cited by 19 · see citing works

AHI-1: a novel signaling protein and potential therapeutic target in human leukemia and brain disorders

Esmailzadeh, S., & Jiang, X. (2011) · Oncotarget · doi:10.18632/oncotarget.405 · Cited by 18 · see citing works

An Approach to the Management of Chronic Myeloid Leukemia in British Columbia

Forrest, D. L., Jiang, X., Eaves, C. J., et al. (2008) · Current Oncology · doi:10.3747/co.v15i2.224 · Cited by 13 · see citing works

Molecular and structural characterization of the SH 3 domain of AHI ‐1 in regulation of cellular resistance of BCR ‐ ABL + chronic myeloid leukemia cells to tyrosine kinase inhibitors

Liu, X., Chen, M., Lobo, P. A., et al. (2012) · PROTEOMICS · doi:10.1002/pmic.201100553 · Cited by 9 · see citing works

Erratum: Corrigendum: Abnormal cerebellar development and axonal decussation due to mutations in AHI1 in Joubert syndrome

Ferland, R. J., Eyaid, W., Collura, R. V., Tully, L. D., Hill, R. S., Al-Nouri, D., Al-Rumayyan, A. R., Topçu, M., Gascon, G. G., Bodell, A., et al. (2004) · Nature Genetics · doi:10.1038/ng1004-1126b · Cited by 8 · see citing works

Cloning and Characterization of the Promoter of the Human AHI1 Gene

Meng, X., Luo, Y., Xiao, W., Li, M., & Shi, J. (2009) · Biochemical Genetics · doi:10.1007/s10528-009-9232-8 · Cited by 4 · see citing works

PP2A Balances Glucose Metabolism and Foxo Activation to Maintain Cellular Redox Homeostasis in Acute Lymphoblastic Leukemia

Xiao, G., Chen, Z., Daniel, B., et al. (2016) · Blood · doi:10.1182/blood.v128.22.1056.1056 · Cited by 1 · see citing works

PP2A holoenzymes, substrate specificity driving cellular functions and deregulation in cancer

(2019) · Advances in Cancer Research · doi:10.1016/bs.acr.2019.03.009 · Cited by 93 · see citing works

The ABL oncogene in human leukemias

Westbrook, C. A. (1988) · Blood Reviews · doi:10.1016/0268-960x(88)90002-1 · Cited by 9 · see citing works

Molecular heterogeneity of adult Philadelphia chromosome-positive acute lymphoblastic leukemia.

Schaefer-Rego, K., Arlin, Z. A., Shapiro, L. G., et al. (1988) · PubMed · Cited by 21 · see citing works

Cell lines and clinical isolates derived from Ph1-positive chronic myelogenous leukemia patients express c-abl proteins with a common structural alteration.

Konopka, J. B., Watanabe, S. M., Singer, J. W., Collins, S., & Witte, O. N. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.6.1810 · Cited by 261 · see citing works

Detection of BCR-ABL proteins in blood cells of benign phase chronic myelogenous leukemia patients.

Guo, J., Wang, J., & Arlinghaus, R. B. (1991) · PubMed · Cited by 49 · see citing works

Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias

Shah, N. P., & Sawyers, C. L. (2003) · Oncogene · doi:10.1038/sj.onc.1206942 · Cited by 215 · see citing works